Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Follow-Up drug keep bones strong after initial osteoporosis therapy?

NCT ID NCT06164795

Disease control Sponsor: 424 General Military Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This study looks at postmenopausal women with severe osteoporosis who have finished a course of either romosozumab or teriparatide. Researchers want to see which follow-up drug—zoledronate, denosumab, teriparatide, romosozumab, or abaloparatide—best maintains or improves bone density. The goal is to find the most effective sequential treatment to reduce fracture risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zoledronate, denosumab, teriparatide, romosozumab, or abaloparatide
What this could lead to
If successful, this study could identify the most effective bone-strengthening drug to use after initial treatment, helping prevent fractures in women with severe osteoporosis.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by patient selection. Differences in bone density may not translate to fewer fractures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Postmenopausal women treated with severe osteoporosis

Ages

50 to 85 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: • Postmenopausal women treated with severe osteoporosis completing their course with romosozumab or teriparatide Exclusion Criteria: * a bone disease other than postmenopausal osteoporosis * use of medications other than romosozumab or teriparatide affecting bone metabolism during the last 12 months before entering the study * creatinine clearance \<60 mL/min/1.73 m2 * liver failure * any type of cancer * uncontrolled endocrine diseases * serum 25-hydroxy vitamin D (25-OHD) concentrations lower than 20 ng/mL (50 nmol/L) * hypersensitivity to denosumab or zoledronate or teriparatide or romosozumab or any of the excipients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoporosis postmenopausal are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postmenopausal osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteoporosis postmenopausal

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • , KAT General Hospital

    RECRUITING

    Athens, 14561, Greece

  • 251 Airforce & VA General Hospital

    RECRUITING

    Athens, 11525, Greece

  • 424 General Military Hospital

    RECRUITING

    Thessaloniki, 56429, Greece

  • Campus Bio-Medico University

    RECRUITING

    Roma, 00128, Italy

  • Department of Medicine, Surgery and Neurosciences, University of Siena

    RECRUITING

    Siena, 53100, Italy

  • First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens

    RECRUITING

    Athens, 11527, Greece

  • Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico

    RECRUITING

    Milan, Italy

  • University-Hospital S. Maria della Misericordia

    RECRUITING

    Udine, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.